Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2004 1
2005 1
2006 2
2007 2
2008 1
2009 2
2010 4
2011 5
2012 6
2013 6
2014 1
2015 10
2016 3
2017 5
2018 4
2019 6
2020 3
2021 6
2022 8
2023 6
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

72 results

Results by year

Filters applied: . Clear all
Page 1
Rivaroxaban Monotherapy vs Combination Therapy With Antiplatelets on Total Thrombotic and Bleeding Events in Atrial Fibrillation With Stable Coronary Artery Disease: A Post Hoc Secondary Analysis of the AFIRE Trial.
Naito R, Miyauchi K, Yasuda S, Kaikita K, Akao M, Ako J, Matoba T, Nakamura M, Hagiwara N, Kimura K, Hirayama A, Matsui K, Ogawa H; AFIRE Investigators. Naito R, et al. JAMA Cardiol. 2022 Aug 1;7(8):787-794. doi: 10.1001/jamacardio.2022.1561. JAMA Cardiol. 2022. PMID: 35704345 Free PMC article. Clinical Trial.
Roles of peptidyl prolyl isomerase Pin1 in viral propagation.
Kanna M, Nakatsu Y, Yamamotoya T, Encinas J, Ito H, Okabe T, Asano T, Sakaguchi T. Kanna M, et al. Among authors: nakatsu y. Front Cell Dev Biol. 2022 Oct 25;10:1005325. doi: 10.3389/fcell.2022.1005325. eCollection 2022. Front Cell Dev Biol. 2022. PMID: 36393854 Free PMC article. Review.
Prolyl isomerase Pin1 in metabolic reprogramming of cancer cells.
Nakatsu Y, Yamamotoya T, Ueda K, Ono H, Inoue MK, Matsunaga Y, Kushiyama A, Sakoda H, Fujishiro M, Matsubara A, Asano T. Nakatsu Y, et al. Cancer Lett. 2020 Feb 1;470:106-114. doi: 10.1016/j.canlet.2019.10.043. Epub 2019 Oct 31. Cancer Lett. 2020. PMID: 31678165 Review.
Development of Pin1 Inhibitors and their Potential as Therapeutic Agents.
Nakatsu Y, Matsunaga Y, Ueda K, Yamamotoya T, Inoue Y, Inoue MK, Mizuno Y, Kushiyama A, Ono H, Fujishiro M, Ito H, Okabe T, Asano T. Nakatsu Y, et al. Curr Med Chem. 2020;27(20):3314-3329. doi: 10.2174/0929867325666181105120911. Curr Med Chem. 2020. PMID: 30394205 Review.
Gut Microbiota as a Therapeutic Target for Metabolic Disorders.
Okubo H, Nakatsu Y, Kushiyama A, Yamamotoya T, Matsunaga Y, Inoue MK, Fujishiro M, Sakoda H, Ohno H, Yoneda M, Ono H, Asano T. Okubo H, et al. Among authors: nakatsu y. Curr Med Chem. 2018;25(9):984-1001. doi: 10.2174/0929867324666171009121702. Curr Med Chem. 2018. PMID: 28990516 Review.
72 results